-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Looking back on the past, looking forward to the future
.
On the occasion of the arrival of 2022, Yimaitong Hematology launched the "Annual Inventory" series of articles, summarizing the research fronts worthy of attention in the field of blood diseases in 2021
.
Today, we bring you a summary of "Diffuse Large B-Cell Lymphoma (DLBCL)", click on the title of the article to read the original text
.
01 Interview with a CSCO Expert: 1.
2021 CSCO Expert Interview｜Professor Zhu Jun: lonca shows preliminary efficacy, and the application prospect of R/R DLBCL new drug is worth looking forward to 2.
2021 CSCO Expert Interview｜Professor Cai Qingqing talks about the treatment of diffuse large B-cell lymphoma Progress 3.
Professor Jin JieDLBCL has entered a new era of precision therapy, and CAR-T therapy brings new hopeProfessor Liu Hui: Stratified treatment strategies guided by DLBCL assessment tools | China Hematology Development Conference 3.
Prof.
Yu Wenjuan: Progress in the diagnosis and treatment of debilitated diffuse large B-cell lymphoma in the elderly2021 Jinling Lymphoma Forum 4.
Prof.
Cao Junning: Clinical features and treatment progress of EBV-positive DLBCLThe 6th Anti-Leukemia ·Lymphoma International Summit Forum 5.
Prof.
Zhao Donglu: Application Progress of Novel Antibodies in Diffuse Large B-Cell Lymphoma | 2021 Leukemia and Lymphoma Summit Forum 6.
2021 CSCOProfessor Bai Ou: DLBCL Prognosis Exploration and Treatment Optimization 7 .
Professor Zhou Hui: Standardized or individualized first-line treatment of DLBCL? | CSCO Anti-Lymphoma Alliance Tour Lecture 8.
Prof.
Liu Wei: The role of transplantation in DLBCL in the era of CAR-T therapy | CSCO Anti-Lymphoma Alliance Tour Lecture 9.
What are the differences in the treatment and prognosis of DLBCL at different primary sites? Come and listen to what Professor Song Yuqin has to say about the interpretation of 03 big coffee: 1.
2021 EHA first report | Zanubrutinib + Lenalidomide + R-CHOP in the treatment of DLBCL 2.
2021 ASH Express | Li Jianyong, Zhu Huayuan: Zanubrutinib, Efficacy evaluation of lenalidomide + R-CHOP in the first-line treatment of newly diagnosed DLBCL 3.
2021 ASH first look | Prof.
Xu Wei interprets the application of anti-CD19 ADC in R/R DLBCL 4.
2021 ASH | Prof.
Qian Wenbin's team: Phase Ib study of novel CAR-T combined with tislelizumab in the treatment of relapsed/refractory DLBCL Demonstrated comprehensive evidence-based evidence in 6.
.
On the occasion of the arrival of 2022, Yimaitong Hematology launched the "Annual Inventory" series of articles, summarizing the research fronts worthy of attention in the field of blood diseases in 2021
.
Today, we bring you a summary of "Diffuse Large B-Cell Lymphoma (DLBCL)", click on the title of the article to read the original text
.
01 Interview with a CSCO Expert: 1.
2021 CSCO Expert Interview｜Professor Zhu Jun: lonca shows preliminary efficacy, and the application prospect of R/R DLBCL new drug is worth looking forward to 2.
2021 CSCO Expert Interview｜Professor Cai Qingqing talks about the treatment of diffuse large B-cell lymphoma Progress 3.
Professor Jin JieDLBCL has entered a new era of precision therapy, and CAR-T therapy brings new hopeProfessor Liu Hui: Stratified treatment strategies guided by DLBCL assessment tools | China Hematology Development Conference 3.
Prof.
Yu Wenjuan: Progress in the diagnosis and treatment of debilitated diffuse large B-cell lymphoma in the elderly2021 Jinling Lymphoma Forum 4.
Prof.
Cao Junning: Clinical features and treatment progress of EBV-positive DLBCLThe 6th Anti-Leukemia ·Lymphoma International Summit Forum 5.
Prof.
Zhao Donglu: Application Progress of Novel Antibodies in Diffuse Large B-Cell Lymphoma | 2021 Leukemia and Lymphoma Summit Forum 6.
2021 CSCOProfessor Bai Ou: DLBCL Prognosis Exploration and Treatment Optimization 7 .
Professor Zhou Hui: Standardized or individualized first-line treatment of DLBCL? | CSCO Anti-Lymphoma Alliance Tour Lecture 8.
Prof.
Liu Wei: The role of transplantation in DLBCL in the era of CAR-T therapy | CSCO Anti-Lymphoma Alliance Tour Lecture 9.
What are the differences in the treatment and prognosis of DLBCL at different primary sites? Come and listen to what Professor Song Yuqin has to say about the interpretation of 03 big coffee: 1.
2021 EHA first report | Zanubrutinib + Lenalidomide + R-CHOP in the treatment of DLBCL 2.
2021 ASH Express | Li Jianyong, Zhu Huayuan: Zanubrutinib, Efficacy evaluation of lenalidomide + R-CHOP in the first-line treatment of newly diagnosed DLBCL 3.
2021 ASH first look | Prof.
Xu Wei interprets the application of anti-CD19 ADC in R/R DLBCL 4.
2021 ASH | Prof.
Qian Wenbin's team: Phase Ib study of novel CAR-T combined with tislelizumab in the treatment of relapsed/refractory DLBCL Demonstrated comprehensive evidence-based evidence in 6.
